Measuring Freezing of Gait in people with Parkinson's disease
Studies new ways to measure freezing of gait in adults with Parkinson's disease.
Plain-language title generated from the registry record
Registry title: Freezing of Gait - Clinical Outcomes Assessment
Key facts
- Where
- Tel Aviv, IsraelSee the site
Where in Israel
- Tel Aviv Saurasky Medical CenterTel Aviv, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel-Aviv Sourasky Medical Center
- Trial code
- NCT06519279
- Record updated
- 28 January 2025
- Original description
To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).Read full original descriptionShow less
An International Multimodal Protocol for Assessing Freezing of Gait in Individuals Living with Parkinson's Disease
To develop a reliable and accurate clinician-reported outcome (ClinRO) measure (against a new and precise definition) and patient reported outcome (PRO) for use by clinicians and researchers to quantify the severity of Freezing of Gait (FOG).
Inclusion: Diagnosis of idiopathic Parkinson's disease (PD) made by a neurologist according to the Movement Disorders Society guidelines; Able to walk independently for a distance of 10 meters, without walking aid; Absence of a Deep Brain Stimulator; Stable PD treatment in the 4 weeks prior to participation that is not expected to change in the course of the study; For patients with FOG: a score of ≥ 1 on the New Freezing Of Gait Questionnaire (NFOG-Q).
Exclusion: Occurrence of any of the following within 3 months prior to informed consent: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), implantation of a cardiac resynchronization therapy device (CRTD), active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse, other neurological (than PD) or orthopaedic impairment that significantly impacts on gait; Unwilling to temporarily delay the morning anti-Parkinsonian medication; Preganacy and.